BR112016007474A2 - diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal - Google Patents

diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal

Info

Publication number
BR112016007474A2
BR112016007474A2 BR112016007474A BR112016007474A BR112016007474A2 BR 112016007474 A2 BR112016007474 A2 BR 112016007474A2 BR 112016007474 A BR112016007474 A BR 112016007474A BR 112016007474 A BR112016007474 A BR 112016007474A BR 112016007474 A2 BR112016007474 A2 BR 112016007474A2
Authority
BR
Brazil
Prior art keywords
treatment
diagnosis
inflammatory bowel
bowel syndrome
irritable bowel
Prior art date
Application number
BR112016007474A
Other languages
English (en)
Portuguese (pt)
Inventor
Chang Christopher
Pimentel Mark
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of BR112016007474A2 publication Critical patent/BR112016007474A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112016007474A 2013-10-09 2014-10-09 diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal BR112016007474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BR112016007474A2 true BR112016007474A2 (pt) 2017-09-12

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007474A BR112016007474A2 (pt) 2013-10-09 2014-10-09 diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal

Country Status (19)

Country Link
US (2) US9851361B2 (enExample)
EP (1) EP3054977B1 (enExample)
JP (1) JP6567509B2 (enExample)
KR (1) KR102259588B1 (enExample)
CN (1) CN105744956B (enExample)
AU (2) AU2014331841B2 (enExample)
BR (1) BR112016007474A2 (enExample)
CA (1) CA2923651C (enExample)
CL (1) CL2016000820A1 (enExample)
ES (1) ES2892905T3 (enExample)
IL (1) IL244971B2 (enExample)
MX (1) MX383423B (enExample)
NZ (1) NZ717633A (enExample)
PE (1) PE20160882A1 (enExample)
PL (1) PL3054977T3 (enExample)
PT (1) PT3054977T (enExample)
RU (1) RU2683781C2 (enExample)
SG (1) SG11201601733VA (enExample)
WO (1) WO2015054529A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
KR102481305B1 (ko) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
DE602004030586D1 (de) * 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
CN102634524B (zh) 2003-12-05 2014-03-05 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2562544A1 (en) 2007-12-20 2013-02-27 InDex Diagnostics AB kits for use in the differentiation of IBD and IBS and further distinction between disease types of IBD
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
AU2010213773B2 (en) 2009-02-11 2014-07-17 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
CA2884413C (en) 2012-09-17 2022-11-01 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
AU2014331841B2 (en) 2013-10-09 2020-03-12 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
SG11201702395WA (en) 2014-10-09 2017-04-27 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10690679B2 (en) 2014-10-09 2020-06-23 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
AU2014331841B2 (en) 2020-03-12
CA2923651A1 (en) 2015-04-16
IL244971B1 (en) 2023-08-01
PL3054977T3 (pl) 2021-12-20
CN105744956A (zh) 2016-07-06
JP6567509B2 (ja) 2019-08-28
HK1221898A1 (zh) 2017-06-16
US20180196063A1 (en) 2018-07-12
IL244971A0 (en) 2016-05-31
NZ717633A (en) 2021-07-30
EP3054977B1 (en) 2021-07-21
CA2923651C (en) 2023-03-14
US10352944B2 (en) 2019-07-16
US9851361B2 (en) 2017-12-26
RU2683781C2 (ru) 2019-04-02
IL244971B2 (en) 2023-12-01
AU2020203468A1 (en) 2020-06-18
US20170038393A1 (en) 2017-02-09
CN105744956B (zh) 2021-07-20
JP2017502253A (ja) 2017-01-19
KR102259588B1 (ko) 2021-06-02
MX2016004167A (es) 2016-06-24
EP3054977A4 (en) 2017-04-12
KR20160062161A (ko) 2016-06-01
PT3054977T (pt) 2021-10-14
RU2016116766A (ru) 2017-11-15
WO2015054529A1 (en) 2015-04-16
ES2892905T3 (es) 2022-02-07
EP3054977A1 (en) 2016-08-17
AU2014331841A1 (en) 2016-03-24
MX383423B (es) 2025-03-14
SG11201601733VA (en) 2016-04-28
CL2016000820A1 (es) 2016-09-23
PE20160882A1 (es) 2016-09-14

Similar Documents

Publication Publication Date Title
BR112016007474A2 (pt) diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
BR112014013082A2 (pt) método para detectar adutos nucleossomos
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112014031613A2 (pt) processo para preparação de conjugados de anticorpos e conjugados de anticorpos
MX2025011654A (es) Anticuerpos contra alfa sinucleina y usos de los mismos
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
BR112017004899A2 (pt) detecção de proteínas mal dobradas
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
BR112012016767A2 (pt) Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
MX2017004516A (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
BR112016017926A2 (pt) ensaio para detectar periostina humana
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
BR112016003030A2 (pt) anticorpos iib do receptor anti-fc-gama e uso dos mesmos
BR112015027249A2 (pt) método de diagnóstico de câncer
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
FR3017111B1 (fr) Dispositif d'assemblage de tuyaux carburant double peau d'un aeronef.
BR112015020874A2 (pt) copropriedade de grupo de recursos acessíveis pela internet
BR112017009605A2 (pt) método para o diagnóstico da doença de niemann-pick usando um biomarcador

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.